Japan's Nitto Denko establishes Nitto BioPharma to focus on pharmaceutical development

Published: 26-Jan-2016
Finance

The firm has an anti-liver fibrosis drug in clinical trials in the US, Europe and Japan


Japanese diversified materials manufacturer Nitto Denko Corporation has formed a new company to focus on pharmaceutical development.

Called Nitto BioPharma, the firm has been conducting its first anti-liver fibrosis drug programme (ND-L02-s0201), which is now in clinical trials in the US, Europe and Japan.

Osaka-based Nitto says Nitto BioPharma has several more pipelines of drugs for intractable diseases in the discovery stage.

Along with the establishment of the new company, by the middle of this year Nitto plans to set up a new facility in the Life Sciences hub in San Diego, CA, US.

Going forward, drug discovery and development ventures, such as the anti-fibrosis drug programme and others, will be conducted by Nitto and the new company.

Nitto BioPharma's activities fall into Nitto's Fine (Life Sciences) business. The firm also plans to expand its Green (Environment) and Clean (New Energy) activities.

  • Companies:
  • Nitto Denko
See more

You may also like

Manufacturing

Nitto Denko takes over Avecia Biotechnology

Read more
Boosts base in emerging nucleic acid drugs market

Trending Articles

  1. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
  2. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  3. Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
  4. AstraZeneca invests $3.5bn into its US pharmaceutical research and manufacturing capabilities The company will expand its biologics manufacturing, as well as its speciality manufacturing and cell therapy production capacity, while also extending its pharmaceutical research and development capabilities through this investment
  5. Evotec strikes up a deal with Monacum Partners to sell its Halle API manufacturing facility The CDMO faction of Evotec will now function as DAPIN GmbH, which will continue to specialise in end-to-end chemical API development and manufacturing

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Manufacturing

Nitto Denko takes over Avecia Biotechnology

Boosts base in emerging nucleic acid drugs market
Finance

Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines

The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways
Research & Development

Syncona launches early-stage drug development company, Slingshot Therapeutics

The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
Manufacturing

Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger

Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
Manufacturing

AstraZeneca invests $3.5bn into its US pharmaceutical research and manufacturing capabilities

The company will expand its biologics manufacturing, as well as its speciality manufacturing and cell therapy production capacity, while also extending its pharmaceutical research and development capabilities through this investment
Manufacturing

Evotec strikes up a deal with Monacum Partners to sell its Halle API manufacturing facility

The CDMO faction of Evotec will now function as DAPIN GmbH, which will continue to specialise in end-to-end chemical API development and manufacturing
Finance

MAP Group broadens its European market access platform by adding SKC to its portfolio of companies

The MAP Group has continued its international expansion with the acquisition of SKC Beratungsgesellschaft mbH, significantly increasing expertise and headcount and expanding its footprint into a key European market
Subscribe now